Getting latest data loading
Home / Morning Report / Morning Report

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Morning Report - 21 February 2022

Yesterday’s UK 100 Leaders Price (p) % Chg
STANDARD CHARTERED PLC 579.2 3.8%
ANTOFAGASTA PLC 1,404.0 2.3%
RECKITT BENCKISER GROUP PLC 6,273.0 2.0%
BURBERRY GROUP PLC 2,033.0 2.0%
AIRTEL AFRICA PLC 153.9 1.7%
Yesterday’s UK 100 Laggards Price (p) % Chg
EVRAZ PLC 283.2 -7.2%
AVEVA GROUP PLC 2519.0 -6.4%
OCADO GROUP PLC 1300.0 -4.5%
FLUTTER ENTERTAINMENT PLC-DI 10530.0 -4.4%
SCOTTISH MORTGAGE INV TR PLC 1015.0 -4.2%
Major World Indices Price % Chg 1 YEAR
UK 100 INDEX 7,514 -0.3% 13.4%
DOW JONES INDUS. AVG 34,079 -0.7% 8.2%
DAX INDEX 15,043 -1.5% 7.5%
NIKKEI 225 26,911 -0.8% -10.4%
S&P/ASX 200 INDEX 7,234 0.2% 6.5%
Commodities Units Price % Chg
WTI Crude Oil (Nymex) USD/bbl. 91.18 0.12%
Brent Crude (ICE) USD/bbl. 93.24 -0.32%
Gold Spot USD/t oz. 1,888 -0.5%
Copper (Comex) USd/lb. 454 0.3%
The UK 100 is called to open +46 points today at 7559.

1 Day; 12 Months

Click graph to enlarge

Markets Overview:

 

The UK 100 is called to open +46 points today at 7559.  The UK 100 looks set to open the day and week in positive territory after France have seemingly worked to get presidents Putin and Biden around the negotiating table to avert conflict, this led to a rally in Asia’s main markets on Monday and looks likely to put a pep in the step of European stocks.  U.S. stock indexes fell on Friday, the blue-chip Dow Jones shed 232.85 points, or 0.7%, to end the session at 34,079.18. The S&P lost 0.7% to close at 4,348.87, while the Nasdaq retreated 1.2% to end the week at 13,548.07.

 

 

Company News & Broker Comments:

 

Company News:

 

AstraZeneca says trial results show Enhertu improved progression-free and overall survival in patients with HER2-low metastatic breast cancer.

 

 

Dechra Pharmaceuticals reported a H1 pretax profit of £53.4m (£35.4m profit last year). Trading at the start of H2 remains strong as major markets are returning to historic levels of growth. They state that future prospects remain excellent.

 

 

Diageo commences their third phase of capital programme as they state £1.7bn of shares will be repurchased in this phase.

 

 

Halma buys International Light Technologies for $26.6m.

Broker Comments

 

No new broker comments

 

 

Reporting Today:

 

Dechra Pharmaceuticals

 

 

 

Reporting Tuesday:

Antofagasta

 

Coca-Cola HBC

 

HSBC

 

Hargreaves Lansdown

 

Intercontinental Hotels Group

 

Smith & Nephew

 

 

 

 

In Focus Today:

 

PBoC Interest Rate Decision

 

German Producer Price Index

 

German Markit PMI Composite

 

EU Markit PMI Composite

 

UK Markit Services PMI

 

 

 

This Week's Ex-Dividends:

 

FTSE 100:

Diageo

 

GlaxoSmithKline

 

AstraZeneca

 

Unilever

 

Standard Chartered

FTSE 250:

Dunelm Group

 

Redrow

 

Witan Investment Trust

 

Plus500

 

BBGI Global Infrastructure S.A.

 

For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.


Back to Top

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.